Donna E. Reece

610 University Avenue
Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 149 publications

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Journal: Lancet (London, England)

Published: April 29, 2026

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Journal: Blood advances

Published: April 03, 2026

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Journal: The New England journal of medicine

Published: December 09, 2025

Mel200 or BuMel conditioning in myeloma: is there a winner?

Mel200 or BuMel conditioning in myeloma: is there a winner?

Journal: Blood

Published: October 09, 2025

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.

Journal: European journal of haematology

Published: October 09, 2025

Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Journal: Blood cancer discovery

Published: September 30, 2025

Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database.

Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database.

Journal: Clinical lymphoma, myeloma & leukemia

Published: August 19, 2025

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias.

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias.

Journal: Blood advances

Published: August 18, 2025

Immunogenicity and Safety of a Third and Subsequent COVID-19 Vaccine Doses in Patients with Plasma Cell Dyscrasias.

Immunogenicity and Safety of a Third and Subsequent COVID-19 Vaccine Doses in Patients with Plasma Cell Dyscrasias.

Journal: Blood advances

Published: August 18, 2025

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database.

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 07, 2025

Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report.

Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report.

Journal: Blood neoplasia

Published: June 02, 2025

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.

Journal: Blood

Published: April 01, 2025

Showing 1-12 of 149

Last Updated: 09/26/2026